BIOGEN INC. 10-K

ITEM 2. PROPERTIES Below is a summary of our significant properties owned and leased as of December 31, 2024. Location Approximate Square Feet Use Owned/Leased U.S. Cambridge, Massachusetts 263,000 Research laboratory and cogeneration plant Owned Cambridge, Massachusetts 729,000 Corporate headquarters and laboratory Leased - Expires 2028 Weston, Massachusetts 357,000 Office Leased - Expires 2025 RTP, North Carolina 1,040,000 Office, laboratory, manufacturing, warehouse Owned Durham, North Carolina 65,000 Warehouse Leased - Expires 2025 Plano, Texas 327,000 Office and laboratory Leased - Expires 2038 International (1) Solothurn, Switzerland 734,000 Manufacturing facility, warehouse and office Owned Baar, Switzerland 81,800 International headquarters Leased - Expires 2028 (1) We also lease office space in other international regions including: the U.K.; Germany; France; Japan; Canada and numerous other countries. Our international lease agreements expire at various dates through the year 2034. In the fourth quarter of 2021 we began construction of a new gene therapy, clinical packaging and other manufacturing facility in RTP, North Carolina to support our gene therapy pipeline across multiple therapeutic areas. The new manufacturing facility will be approximately 197,000 square feet. We estimate the construction of this manufacturing facility will be completed during 2025. We believe that our our existing properties, including both owned and leased sites, are adequate and suitable for the conduct of our business. We believe our capital resources are sufficient to purchase, lease or construct any additional facilities required to meet our expected long-term growth needs. ITEM 3. LEGAL PROCEEDINGS For a discussion of legal matters as of December 31, 2024, please read Note 21, Litigation, to our consolidated financial statements included in this report, which is incorporated into this item by reference. ITEM 4. MINE SAFETY DISCLOSURES Not applicable. 54 Table o f Contents PART II